Lurasidone Hydrochloride Intermediate CAS 14805-29-9 Purity ≥99.0% (HPLC)
| Chemical Name | (3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione |
| Synonyms | exo-2,3-Norbornanedicarboximide; Lurasidon Hydrochloride Intermediate |
| CAS Number | 14805-29-9 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C9H11NO2 |
| Molecular Weight | 165.19 |
| Melting Point | 150.0~154.0℃ |
| Density | 1.285 |
| Shipping Condition | Shipped Under Ambient Temperature as Non-Hazardous Chemical |
| COA & MSDS | Available |
| Place of Origin | Shanghai, China |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Almost White Powder |
| Melting Point | 150.0~154.0℃ |
| Differentiate | H-NMR |
| Related Compound | ≤0.50% |
| Endo Isomer | ≤0.15% |
| Impurity A | ≤0.10% (3aR,4S,7R,7aS) 4,7-Methano-1H-isoindole-1,3(2H)-dione |
| Max. Single Impurity | ≤0.30% |
| Total Impurities | ≤1.00% |
| Water Content | ≤1.00% |
| Heavy Metals | ≤20ppm |
| Purity / Analysis Method | ≥99.0% (HPLC) |
| Test Standard | Enterprise Standard |
| Usage | Lurasidon Hydrochloride (CAS 367514-88-3) Intermediate |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione (CAS 14805-29-9) with high quality, commercial production. It is an intermediate typically in the synthesis of Lurasidon Hydrochloride (CAS 367514-88-3) in the treatment of Schizophrenia.
Lurasidone was approved by the FDA in 2010 for schizophrenia and in 2013 for depressive episodes associated with bipolar disorder. Lurasidone is an orally administered substance that belongs to the class of atypical antipsychotic drugs (AAPD). It received approval by the EMA in 2014 for schizophrenia. Lurasidone has also been launched in a number of countries outside the US and EU, including Canada, where it is approved for both indications. It is produced through a multi-step chemical process.
